ReShape Lifesciences Files 8-K on Shareholder Vote Submission

TL;DR

**ReShape Lifesciences just filed an 8-K about a shareholder vote, so keep an eye out for what they're asking investors to approve.**

AI Summary

ReShape Lifesciences Inc. filed an 8-K on February 26, 2024, reporting an event that occurred on February 23, 2024. The filing, under SEC File Number 001-37897, indicates the submission of matters to a vote of security holders. The company, incorporated in Delaware, maintains its principal executive offices at 18 Technology Drive, Suite 110, Irvine, CA 92618.

Why It Matters

This filing signals that ReShape Lifesciences is putting significant matters before its shareholders, which could lead to changes in company strategy, governance, or capital structure.

Risk Assessment

Risk Level: medium — The filing indicates a shareholder vote, which could involve significant corporate actions that may impact the company's future and stock price, introducing uncertainty.

Key Players & Entities

• ReShape Lifesciences Inc. (company) — Registrant
• February 23, 2024 (date) — Date of earliest event reported
• February 26, 2024 (date) — Filing date
• Delaware (company) — State of incorporation
• 001-37897 (dollar_amount) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value per share RSLS The Nasdaq

Filing Documents

• rsls-20240223x8k.htm (8-K) — 60KB
• 0001558370-24-001707.txt ( ) — 175KB
• rsls-20240223.xsd (EX-101.SCH) — 3KB
• rsls-20240223_lab.xml (EX-101.LAB) — 15KB
• rsls-20240223_pre.xml (EX-101.PRE) — 10KB
• rsls-20240223x8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. ReShape Lifesciences Inc. (the "Company") held its annual meeting of stockholders on February 23, 2024 (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved each of the following proposals set forth in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on January 24, 2024: Proposal 1 : The Company's stockholders elected Dan W. Gladney and Lori McDougal as Class I directors to hold office until the 2026 annual meeting of stockholders or until his or her successor is elected and qualified, or, if sooner, until his or her death, resignation or removal, as set forth below. Votes For Votes Withheld Broker Non-Votes Dan W. Gladney 1,387,535 631,636 6,332,883 Lori McDougal 1,511,604 507,567 6,332,883 Proposal 2 : The Company's stockholders authorized the Company's Board of Directors (the "Board"), in its discretion but in no event later than February 23, 2025, which is one year after the date of the Annual Meeting, to amend the Company's Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's common stock, at a ratio in the range of 1-for-10 to 1-for-60, such ratio to be determined by the Board and included in a public announcement, as set forth below. Votes For Votes Against Abstentions 5,751,242 2,584,917 15,895 Proposal 3 : The Company's stockholders approved the issuance of shares of the Company's common stock underlying warrants issued to an investor pursuant to that certain Inducement Offer to Exercise Common Stock Purchase Warrants, dated as of November 21, 2023, in an amount equal to 20% or more of the Company's common stock outstanding before the issuance of such warrants upon the operation of anti-dilution provisions contained in such warrants, as required by and in accordance with Nasdaq Listing Rule 5635(d), as set forth below. Vote

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RESHAPE LIFESCIENCES INC. By: /s/ Paul F. Hickey Paul F. Hickey President and Chief Executive Officer Dated: February 26, 2024

View Full Filing

View this 8-K filing on SEC EDGAR